$VRPX
Virpax Pharmaceuticals, Inc. Stock $vrpx

$vrpx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022048047 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.910M	$2.646M	$1.782M
YoY Change	216.46%	33.01%	40.35%
% of Gross Profit
Research & Development	$2.805M	$3.258M	$3.341M
YoY Change	601.28%	929.32%	209.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$7.715M	$5.904M	$5.124M
YoY Change	1828.79%	156.08%	118.03%
Operating Profit	-$7.715M	-$5.904M	-$5.124M
YoY Change	137.41%	156.08%
Interest Expense			$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$73.25K	$19.37K	-$13.18K
YoY Change	16.42%	-605.74%
Pretax Income	-$7.642M	-$5.885M	-$5.137M
YoY Change	137.64%	151.12%	115.84%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$7.642M	-$5.885M	-$5.137M
YoY Change	137.64%	151.12%	115.91%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.65	-$0.50	-$0.44
Diluted Earnings Per Share	-$0.65	-$0.50	-$438.7K
COMMON SHARES
Basic Shares Outstanding	11.71M shares	11.71M shares	11.71M shares
Diluted Shares Outstanding	11.71M shares	11.71M shares	11.71M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$20.56M	$26.06M	$30.80M
YoY Change	-50.71%	148.99%	151.2%
Cash & Equivalents	$20.56M	$26.06M	$30.80M
Short-Term Investments
Other Short-Term Assets	$3.073M	$3.341M	$3.949M
YoY Change	97.05%	262.82%	311.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$23.64M	$29.40M	$34.75M
YoY Change	-45.38%	158.19%	162.83%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$23.64M	$29.40M	$34.75M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$23.64M	$29.40M	$34.75M
YoY Change	-45.38%	158.19%	162.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.000M
YoY Change
Accrued Expenses	$311.2K	$235.6K	$155.9K
YoY Change		-19.15%	-40.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.208M	$2.483M	$2.187M
YoY Change	132.25%	-12.26%	-17.16%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.208M	$2.483M	$2.187M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.208M	$2.483M	$2.187M
YoY Change	132.25%	-35.53%	-40.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.37M	-$33.73M
YoY Change
Common Stock	$117.00	$117.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.43M	$26.92M	$32.56M
YoY Change
Total Liabilities & Shareholders Equity	$23.64M	$29.40M	$34.75M
YoY Change	-45.38%	158.19%	162.83%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$7.642M	-$5.885M	-$5.137M
YoY Change	137.64%	151.12%	115.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$5.499M	-$4.736M	-$6.045M
YoY Change	15.94%	163.44%	96.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.499M	-4.736M	-6.045M
Cash From Investing Activities
Cash From Financing Activities	0.000	0.000
Net Change In Cash	-5.499M	-4.736M	$0.00
YoY Change	-117.6%	163.4%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$5.499M	-$4.736M	-$6.045M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60188535	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37484745	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39572436	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40064
	dei	Entity Registrant Name EntityRegistrantName	VIRPAX PHARMACEUTICALS, INC.
	dei	Local Phone Number LocalPhoneNumber	727-4597
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
	dei	Trading Symbol TradingSymbol	VRPX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1510982
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1055 Westlakes Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berwyn
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19312
	dei	City Area Code CityAreaCode	(610)
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11714565	shares
CY2022Q2	us-gaap	Cash Cash	26061135	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3341307	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	29402442	usd
CY2022Q2	us-gaap	Assets Assets	29402442	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2483373	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2483373	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2483373	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11714565	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11714565	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11714885	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11714885	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	117	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	117	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60644576	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33725624	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22703907	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	26919069	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29402442	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2645618	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1988972	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4428031	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3262544	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3258471	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	316565	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6599877	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1391565	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5904089	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2305537	usd
	us-gaap	Operating Expenses OperatingExpenses	11027908	usd
	us-gaap	Operating Expenses OperatingExpenses	4654109	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5904089	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2305537	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11027908	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4654109	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	34049	usd
	us-gaap	Interest Expense InterestExpense	64748	usd
CY2022Q2	us-gaap	Other Income OtherIncome	19374	usd
CY2021Q2	us-gaap	Other Income OtherIncome	-3833	usd
	us-gaap	Other Income OtherIncome	6191	usd
	us-gaap	Other Income OtherIncome	-3833	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5884715	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2343419	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11021717	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4722690	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5884715	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2343419	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11021717	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4722690	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.5
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11712753	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4958999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11710733	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4454877	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4216098	usd
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2216793	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15783207	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	369884	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2379271	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9557722	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	321427	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-2343419	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7535730	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	37484745	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	211340	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5137002	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	32559083	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	244701	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5884715	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26919069	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11021717	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4722690	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	64748	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	456041	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	691311	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	610863	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	902649	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	395682	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8469	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10780857	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4877749	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	493480	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	100000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2216793	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15289727	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10780857	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10411978	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36841992	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54796	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26061135	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10466774	usd
	us-gaap	Interest Paid Net InterestPaidNet	34707	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	11021717	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	4722690	usd
CY2022Q2	us-gaap	Investment Company Distributable Earnings InvestmentCompanyDistributableEarnings	33725624	usd
CY2021Q3	us-gaap	Shares Issued SharesIssued	6670000	shares
CY2021Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	40000000	usd
	vrpx	Net Proceeds Received From Offering NetProceedsReceivedFromOffering	37000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b> — The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant items subject to such estimates and assumptions include research and development accruals and prepaid expenses, and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Dividends Cash DividendsCash	26061135	usd
CY2021	us-gaap	Dividends Cash DividendsCash	36841992	usd
CY2021Q4	vrpx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	930561	usd
	vrpx	Tax Benefit TaxBenefit	0.50	pure
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	750630	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	152801	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2550472	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2466140	usd
CY2022Q2	vrpx	Legal Retainer LegalRetainer	3050	usd
CY2021Q4	vrpx	Legal Retainer LegalRetainer	103050	usd
CY2022Q2	vrpx	Consulting Fees ConsultingFees	4177	usd
CY2021Q4	vrpx	Consulting Fees ConsultingFees	8453	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	32978	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3341307	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2730444	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	691311	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	383454	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	672877	usd
CY2022Q2	vrpx	Accrued Payroll AccruedPayroll	235612	usd
CY2021Q4	vrpx	Accrued Payroll AccruedPayroll	627281	usd
CY2022Q2	vrpx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	862602	usd
CY2022Q2	vrpx	Insurance Premiums InsurancePremiums	-482048	usd
CY2022Q2	vrpx	Accrued Liabilities Legal Expenses AccruedLiabilitiesLegalExpenses	842722	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q4	vrpx	Accrued Liabilities Legal Expenses AccruedLiabilitiesLegalExpenses	510008	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	27633	usd
CY2022Q2	vrpx	Accrued Accounting Consulting Fees AccruedAccountingConsultingFees	4517	usd
CY2021Q4	vrpx	Accrued Accounting Consulting Fees AccruedAccountingConsultingFees	4166	usd
CY2022Q2	vrpx	Accrued Tax Expenses AccruedTaxExpenses	8000	usd
CY2021Q4	vrpx	Accrued Tax Expenses AccruedTaxExpenses	8000	usd
CY2022Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	20239	usd
CY2021Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	7675	usd
CY2022Q2	vrpx	Account Payable And Accrued Liabilities Current AccountPayableAndAccruedLiabilitiesCurrent	2483373	usd
CY2021Q4	vrpx	Account Payable And Accrued Liabilities Current AccountPayableAndAccruedLiabilitiesCurrent	2087691	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
	vrpx	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	90000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	12.5
	vrpx	Initial Public Offering Percentage InitialPublicOfferingPercentage	1.25	pure
	vrpx	Number Of Complex And Subjective Variables NumberOfComplexAndSubjectiveVariables	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1	pure
	vrpx	Share Based Compensation Arrangement By Share Based Payments Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentsAwardFairValueAssumptionsRiskFreeInterestRate	0.006	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18436	shares
	vrpx	Restricted Stock Awards Description RestrictedStockAwardsDescription	there were 1,185 and 6,196 of unvested restricted stock awards issued totaling $11,718 and $39,862, respectively, based on a fair value of the Company’s common stock on the respective date of grant.During the three months ended June 30, 2022 and 2021, there were 0 and 15,000 restricted stock awards granted during the periods, respectively, and 160 shares of restricted stock awards were forfeited during both the three and six months ended June 30, 2022. The Company recognized $6,132 and $20,568 of stock based compensation for vested restricted shares during the three months ended June 30, 2022 and June 30, 2021, respectively. In addition, during the six months ended June 30, 2022 and 2021, there were 0 and 15,000 restricted stock awards granted during the periods, respectively, and 320 of restricted stock awards forfeited during the six months ended June 30, 2022. The Company recognized $28,144 and $34,629 of stock based compensation for vested restricted shares during the six months ended June 30, 2022 and June 30, 2021, respectively.
	vrpx	Shares Of Common Stock Outstanding Percentage SharesOfCommonStockOutstandingPercentage	0.06	pure
CY2020Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	20225	shares
CY2020Q2	vrpx	Stockbased Compensation Excercisable Percentage StockbasedCompensationExcercisablePercentage	1	pure
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1	pure
CY2020Q2	vrpx	Stock Options To Purchase Common Shares StockOptionsToPurchaseCommonShares	3033	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	244701	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	321427	usd
CY2022Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	208206	usd
CY2021Q2	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	302993	usd
CY2022Q2	vrpx	Stockbased Compensation Within Research And Development Expense StockbasedCompensationWithinResearchAndDevelopmentExpense	36495	usd
CY2021Q2	vrpx	Stockbased Compensation Within Research And Development Expense StockbasedCompensationWithinResearchAndDevelopmentExpense	18433	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	456041	usd
	vrpx	Stockbased Compensation Within Research And Development Expense StockbasedCompensationWithinResearchAndDevelopmentExpense	72587	usd
	vrpx	Stockbased Compensation Within Research And Development Expense StockbasedCompensationWithinResearchAndDevelopmentExpense	18433	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0105	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7694	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.794	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	486101	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.89
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M4D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.62
CY2021	vrpx	Stocks Issued During Period Shares Stock Options Exercised StocksIssuedDuringPeriodSharesStockOptionsExercised	87751	shares
CY2021	vrpx	Weighted Average Exercise Price Exercisedin Shares WeightedAverageExercisePriceExercisedinShares	9.89
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	275717	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.62
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	669067	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.75
CY2021	vrpx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	518805	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.26
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1187872	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
	vrpx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M17D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	600509	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.83
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M29D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	321204	usd
	vrpx	Exercise Price Per Share ExercisePricePerShare	2.13
	us-gaap	Deferred Compensation Arrangement With Individual Exercise Price DeferredCompensationArrangementWithIndividualExercisePrice	2.34
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	77601	shares
CY2022Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	3.43
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	60000	shares
CY2022Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	1.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease	60000	shares
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	1.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.98
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.09
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	801470	usd
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P2Y25D
CY2019Q1	vrpx	Related Party Loan Principal RelatedPartyLoanPrincipal	1000000	usd
	vrpx	Related Party Loan Principal RelatedPartyLoanPrincipal	1000000	usd
CY2018Q1	vrpx	Description Of Lipocure Agreement DescriptionOfLipocureAgreement	the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
CY2019Q2	vrpx	Nanomerics Collaboration Agreement Description NanomericsCollaborationAgreementDescription	the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development.
CY2021Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	400000	usd
	vrpx	Research And Development Expenses ResearchAndDevelopmentExpenses	630000	usd
	vrpx	Research And Development Expenses ResearchAndDevelopmentExpenses	0	usd
CY2020Q3	vrpx	Cooperative Research And Development Agreement Description CooperativeResearchAndDevelopmentAgreementDescription	The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent.
	vrpx	Evergreen Provision Percentage EvergreenProvisionPercentage	0.02	pure
	vrpx	Aggregate Reserves Plan Description AggregateReservesPlanDescription	(i) 1,500,000 shares of our common stock for the issuance of awards under the 2022 Plan (all of which may be granted as ISOs), plus (ii) an additional number of shares of common stock subject to outstanding awards under the 2017 Plan that become forfeited or canceled without payment or which are surrendered in payment of the exercise price and/or withholding taxes (collectively, the “Share Limit”). Pursuant to the 2022 Plan’s “evergreen” provision, the Share Limit shall be cumulatively increased on January 1, 2023, and on each January 1 thereafter, by 2% of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares as determined by our board of directors.
	dei	Entity Central Index Key EntityCentralIndexKey	0001708331
	vrpx	Nonemployee Description NonemployeeDescription	●on January 1 of each year, each non-employee director will be granted Stock Options under the 2022 Plan to purchase 15,000 shares of our common stock. ●each new non-employee director will be granted Stock Options under the 2022 Plan to purchase up to 25,000 shares of our common stock, as determined by the Compensation Committee, at the time the individual first becomes a director. ●on January 1, of each year, each then serving non-Chair member of the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee shall automatically be granted Stock Options to purchase 5,000 shares of common stock under the 2022 Plan, and the Chair of the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee and the Science and Technology Committee shall each be granted Stock Options to purchase 10,000 shares of common stock under the 2022 Plan.
	vrpx	Expiration Date Description ExpirationDateDescription	All such options will become exercisable on the one-year anniversary of the date of grant
CY2021Q2	vrpx	Stock Issued During Period Value Restricted Stock Award Granted Value StockIssuedDuringPeriodValueRestrictedStockAwardGrantedValue		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2021Q4	vrpx	Insurance Premiums InsurancePremiums		usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent		usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2021	vrpx	Weighted Average Remaining Contractual Term Years Granted WeightedAverageRemainingContractualTermYearsGranted
CY2021Q4	vrpx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodIntrinsicValue		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
	vrpx	Weighted Average Remaining Contractual Term Years Granted WeightedAverageRemainingContractualTermYearsGranted
CY2022Q2	vrpx	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodIntrinsicValue		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2

Files In Submission

Name	View Source	Status
0001213900-22-048047-index-headers.html	Edgar Link	pending
0001213900-22-048047-index.html	Edgar Link	pending
0001213900-22-048047.txt	Edgar Link	pending
0001213900-22-048047-xbrl.zip	Edgar Link	pending
f10q0622ex31-1_virpaxpharma.htm	Edgar Link	pending
f10q0622ex31-2_virpaxpharma.htm	Edgar Link	pending
f10q0622ex32-1_virpaxpharma.htm	Edgar Link	pending
f10q0622ex32-2_virpaxpharma.htm	Edgar Link	pending
f10q0622_virpaxpharma.htm	Edgar Link	pending
f10q0622_virpaxpharma_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrpx-20220630.xsd	Edgar Link	pending
vrpx-20220630_cal.xml	Edgar Link	unprocessable
vrpx-20220630_def.xml	Edgar Link	unprocessable
vrpx-20220630_pre.xml	Edgar Link	unprocessable
vrpx-20220630_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRPX
Virpax Pharmaceuticals, Inc. Stock $vrpx

2022 Q3 Form 10-Q Financial Statement

#000121390022048047 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRPX Virpax Pharmaceuticals, Inc. Stock $vrpx

2022 Q3 Form 10-Q Financial Statement

#000121390022048047 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRPX
Virpax Pharmaceuticals, Inc. Stock $vrpx